Leveraging Advanced Omics to Uncover Fibrotic Pathomechanisms & Identify Novel Approaches, Evaluate Biomarker Strategy, & Assess Antifibrotics in an Evolving Landscape to Cement Candidate Confidence
The antifibrotic field is at an inflection point: Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, Boehringer’s nerandomilast hit its Phase 3 endpoint in IPF, and pharma giants like Lilly and GSK are investing billions in fibrosis pipelines. Yet, with GLP-1s reshaping metabolic disease treatment and organ-specific challenges persisting, developers must now prove differentiation, whether through novel targets, biomarker strategies, or pan-fibrotic mechanisms.
Tackle these shared challenges alongside 80+ leaders from Pfizer, Novartis, Gilead Sciences, and pioneering biotechs at the 9th Antifibrotic Drug Development Summit - the only cross-fibrosis industry summit bridging discovery to Phase 2, across IPF, MASH, kidney, cardiac, and systemic sclerosis fibrosis.
Download the Full Event Guide to Discover:
- 80+ industry leaders from top pharma, biotech, and academic organisations
- Actionable strategies across IPF, MASH, kidney, cardiac, and gut fibrosis, all in one place
- Exclusive data recent approvals and Phase 2 successes
- Cutting-edge science including spatial omics, ADCs, and collagen-targeted PET imaging with pioneers
- 8+ hours of tailored networking opportunities
World-Class Speaker Faculty Includes:
Kevin Hart
Associate Research Fellow, Scientific Director, Fibrosis Exploratory Biology and Drug Discovery Group
Pfizer
“This conference allowed me to get up to date with the large (and growing) amount of effort in the field of fibrosis. There's no other way to get so much information in 2-3 days. Very informative.”
Neuraly
"Very dynamic interactions and vibrant discussions excellent with experts from the field."
Development Center for Biotechnology
"Excellently organized, the workshops and conference went smoothly and offered ample opportunity to get in contact with colleagues and for networking; it is not a question of one single highlight, the overall concept worked out nicely."
Vivoryon Therapeutics
Our Partners:
